Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

li id=cr1Pamela Taxel li id=cr2Robert Dowsett li id=cr3Lee Richter li id=cr4Pamela Fall li id=cr5Alison Klepinger li id=cr6Peter Albertsen

首页> 外文期刊>BJU International >Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

【24h】

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

机译：利塞膦酸可预防黄体化激素释放激素激动剂治疗前列腺癌的前6个月中早期骨丢失和增加骨转换

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Study Type – Therapy (RCT) Level of Evidence 1b

机译：研究类型–治疗（RCT）证据等级1b

著录项

来源
《BJU International》 |2010年第10期|p.1473-1476|共4页
作者
li id=cr1Pamela Taxel li id=cr2Robert Dowsett li id=cr3Lee Richter li id=cr4Pamela Fall li id=cr5Alison Klepinger li id=cr6Peter Albertsen;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词
androgen deprivation; prostate cancer; osteoporosis;

机译：雄激素剥夺;前列腺癌;骨质疏松;

相似文献

外文文献
中文文献
专利

1. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. [J] . Taxel P, Dowsett R, Richter L, BJU international . 2010,第10期

机译：在对前列腺癌进行黄体化激素释放激素激动剂治疗的前6个月中，利塞膦酸钠可防止早期骨丢失和增加骨转换。
2. 865 POSTER Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen blockade with luteinizing hormone-releasing hormone analogues [J] . European Journal of Cancer Supplements . 2005,第2期

机译：865 POSTER唑来膦酸通过黄体生成激素释放激素类似物减少雄激素阻断的前列腺癌男性的骨质流失
3. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer. [J] . Weston R, Hussain A, George E, BJU international . 2005,第6期

机译：骨质疏松症前列腺癌患者停止长期黄体生成激素释放激素类似物治疗后，睾丸激素恢复和骨矿物质密度变化。
4. Synergistic role of Hydroxyapatite Nanoparticles and Pulsed Electromagnetic Field Therapy to prevent Bone loss in rats following exposed to Simulated Microgravity [C] . Divya Prakash, J. Behari International Conference of Recent Advances in Microwave Theoty and Applications . 2008

机译：羟基磷灰石纳米颗粒和脉冲电磁场治疗的协同作用，以防止大鼠骨质损失暴露于模拟微匍匐
5. Changes in bone mineral density in men with prostate cancer during treatment with luteinizing hormone-releasing hormone (LHRH) agonist monotherapy. [D] . Conde, Francisco Alcasid, II. 2003

机译：黄体激素释放激素（LHRH）激动剂单药治疗期间前列腺癌男性的骨矿物质密度变化。
6. Exercise training in obese older adults prevents increase in bone turnover and attenuates decrease in hip BMD induced by weight loss despite decline in bone-active hormones [O] . Krupa Shah, Reina Armamento-Villareal, Nehu Parimi, -1

机译：尽管骨骼活性激素下降但在肥胖的成年人中进行运动训练可防止骨骼代谢增加并减轻体重减轻引起的髋部BMD下降
7. Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: Results of a 2-year follow-up study [O] . Izumi, Kouji 　, Mizokami, Atsushi, Sugimoto, Kazuhiro, 2011

机译：Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: Results of a 2-year follow-up study

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅